Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRAB NASDAQ:TDUP OTCMKTS:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRABGrab$3.93+1.3%$3.60$3.18▼$6.62$15.90B0.8749.51 million shs24.88 million shsTDUPThredUp$6.60+0.5%$5.31$3.08▼$12.28$848.44M1.971.88 million shs991,440 shsVXRTVaxart$0.55-0.2%$0.61$0.31▼$0.84$132.90M1.09314,656 shs331,273 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRABGrab+1.29%+0.77%+20.18%+6.79%-21.24%TDUPThredUp+0.46%-6.12%+36.65%+75.53%-1.79%VXRTVaxart-0.24%-14.69%-7.46%-13.33%+82.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRABGrab$3.93+1.3%$3.60$3.18▼$6.62$15.90B0.8749.51 million shs24.88 million shsTDUPThredUp$6.60+0.5%$5.31$3.08▼$12.28$848.44M1.971.88 million shs991,440 shsVXRTVaxart$0.55-0.2%$0.61$0.31▼$0.84$132.90M1.09314,656 shs331,273 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRABGrab+1.29%+0.77%+20.18%+6.79%-21.24%TDUPThredUp+0.46%-6.12%+36.65%+75.53%-1.79%VXRTVaxart-0.24%-14.69%-7.46%-13.33%+82.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRABGrab 2.91Moderate Buy$6.0152.81% UpsideTDUPThredUp 2.86Moderate Buy$9.1438.48% UpsideVXRTVaxart 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest GRAB, TDUP, and VXRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026GRABGrab BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$7.00 ➝ $5.007/9/2026VXRTVaxart Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/30/2026GRABGrab Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$6.256/24/2026TDUPThredUp Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/2/2026GRABGrab Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/6/2026GRABGrab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/6/2026GRABGrab Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.905/6/2026GRABGrab China RenaissanceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$5.005/5/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.705/5/2026TDUPThredUp Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $8.005/5/2026GRABGrab JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$5.90 ➝ $5.80(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRABGrab$3.37B4.78$0.11 per share35.73$1.65 per share2.38TDUPThredUp$310.81M2.74N/AN/A$0.47 per share14.04VXRTVaxart$237.26M0.56$0.10 per share5.34$0.37 per share1.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRABGrab$268M$0.01393.3926.201.5310.67%5.79%3.28%7/30/2026 (Estimated)TDUPThredUp-$20.21M-$0.16N/AN/AN/A-6.68%-36.11%-12.53%8/5/2026 (Estimated)VXRTVaxart$16.33M$0.153.64N/AN/A14.51%61.43%20.07%8/12/2026 (Estimated)Latest GRAB, TDUP, and VXRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026TDUPThredUp-$0.03N/AN/AN/A$90.34 millionN/A7/30/2026Q2 2026GRABGrab$0.01N/AN/AN/A$989.86 millionN/A5/7/2026Q1 2026VXRTVaxart$0.02$0.02N/A$0.02$50.50 million$39.23 million5/5/2026Q1 2026GRABGrab$0.0188-$0.01-$0.0288-$0.01$921.71 million$955.00 million5/4/2026Q1 2026TDUPThredUp-$0.05-$0.05N/A-$0.05$80.17 million$81.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGRABGrabN/AN/AN/AN/AN/ATDUPThredUpN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRABGrab0.061.671.65TDUPThredUp0.300.950.95VXRTVaxartN/A1.711.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRABGrab55.52%TDUPThredUp89.08%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipGRABGrab3.60%TDUPThredUp23.10%VXRTVaxart2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRABGrab12,0124.10 billion3.95 billionOptionableTDUPThredUp2,132129.04 million99.23 millionOptionableVXRTVaxart120242.84 million236.04 millionNo DataGRAB, TDUP, and VXRT HeadlinesRecent News About These CompaniesVaxart (OTCMKTS:VXRT) Stock Rating Upgraded by Zacks ResearchJuly 11 at 9:41 AM | marketbeat.comVaxart (OTCMKTS:VXRT) Share Price Passes Below 200 Day Moving Average - Here's What HappenedJuly 10 at 3:59 AM | marketbeat.comVaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 VaccineJuly 6, 2026 | finance.yahoo.comVaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 VaccineJuly 6, 2026 | globenewswire.comVaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance EnhancementsJuly 1, 2026 | finance.yahoo.comVaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance EnhancementsJuly 1, 2026 | globenewswire.comVaxart (OTCMKTS:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - What's Next?July 1, 2026 | americanbankingnews.comVaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAYJune 27, 2026 | markets.businessinsider.comVaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAYJune 26, 2026 | globenewswire.comVaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine TrialJune 25, 2026 | finance.yahoo.comVaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine TrialJune 25, 2026 | globenewswire.comVaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual MeetingJune 16, 2026 | finance.yahoo.comVaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual MeetingJune 16, 2026 | globenewswire.comVaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech ForumJune 15, 2026 | finance.yahoo.comVaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech ForumJune 15, 2026 | globenewswire.comVaxart to Participate in BTIG Infectious Disease Day 2026June 9, 2026 | finance.yahoo.comVaxart to Participate in BTIG Infectious Disease Day 2026June 9, 2026 | globenewswire.comVaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAYJune 8, 2026 | finance.yahoo.comVaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAYJune 8, 2026 | globenewswire.comVaxart Files Definitive Proxy Statement and Mails Letter to ShareholdersJune 1, 2026 | globenewswire.comVaxart Files Preliminary Proxy Statement and Issues Open Letter to ShareholdersMay 19, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20263 Penny Stocks Under $5 Backed by Real Revenue GrowthBy Chris Markoch | June 20, 2026Rackspace’s AI Land Grab: Plugging Into the Next Compute BoomBy Jeffrey Neal Johnson | June 19, 2026GRAB, TDUP, and VXRT Company DescriptionsGrab NASDAQ:GRAB$3.93 +0.05 (+1.29%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$3.96 +0.03 (+0.89%) As of 07/10/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grab Holdings Limited engages in the provision of superapps in Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. The company offers its Grab ecosystem, a single platform with superapps for driver- and merchant-partners and consumers, that allows access to mobility, delivery, digital financial services, and enterprise sector offerings. Grab Holdings Limited is headquartered in Singapore.ThredUp NASDAQ:TDUP$6.60 +0.03 (+0.46%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$6.48 -0.11 (-1.74%) As of 07/10/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California.Vaxart OTCMKTS:VXRT$0.55 0.00 (-0.24%) As of 07/10/2026 03:58 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
